NEW YORK (GenomeWeb News) – Reaction Biology has reeled in a $1.2 million small business innovation research grant from the National Cancer Institute that it will use to expand an epigenetics-related drug discovery screening platform, the company said today.
The Malvern, Pa.-based firm plans to use the two-year grant to expand its Methyltransferase HotSpotSM drug discovery screens from 14 to 35 or more, the company said.
"Epigenetic mechanisms are increasingly recognized as fundamental to several cancers and many other diseases," Reaction Biology Chief Technology Officer Haiching Ma said in a statement. Ma hopes that its screening capability will fill a need for a cost-effective option for methyltransferase screening and profiling needs.
The HotSpot technology is an ultra-low volume, tritium-based assay platform that is offered as a screening service.